Trial to assess the tolerability of using felodipine to upregulate autophagy as a treatment of Huntington’s disease (FELL-HD): a phase II, single-centre, open-label, dose-finding trial protocol

Authors

Katherine Bongaerts
David C. Rubinsztein (ORCID: https://orcid.org/0000-0001-5002-5263)
Laura Oakley
Alimu Dayimu (ORCID: https://orcid.org/0000-0001-9998-7463)
Emma Cutting
Robyn Staples
Roger A. Barker (ORCID: https://orcid.org/0000-0001-8843-7730)
Katie Andresen (ORCID: https://orcid.org/0009-0007-4827-7753)
Nikolaos Demiris
Dimitrios Apostolopoulos
Wendy Gooding
Amy H Evans

Institutions

University of Cambridge (GB)
Cambridge University Hospitals NHS Foundation Trust (GB)
MRC Clinical Trials Unit at UCL (GB)
UK Dementia Research Institute (GB)
Institute for Medical Research (MY)

Publication Details

Journal: BMJ Open
Published: 2024-08-01
DOI: https://doi.org/10.1136/bmjopen-2024-087983
Citations: 3
Primary Topic: Genetic Neurodegenerative Diseases
Type: article
Field-Weighted Citation Impact: 0.80

Funders

National Institute for Health and Care Research
Department of Health and Social Care
University of Cambridge
Cambridge University Hospitals
UK Dementia Research Institute
Medical Research Council
NIHR Cambridge Biomedical Research Centre

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Trial to assess the tolerability of using felodipine to upregulate autophagy as a treatment of Huntington’s disease (FELL-HD): a phase II, single-centre, open-label, dose-finding trial protocol

Katherine Bongaerts, David C. Rubinsztein, Laura Oakley, Alimu Dayimu et al.

Aug 1, 2024

3 citations

BMJ Open

Genetic Neurodegenerative Diseases

0.80

article

Trial to assess the tolerability of using felodipine to upregulate autophagy as a treatment of Huntington’s disease (FELL-HD): a phase II, single-centre, open-label, dose-finding trial protocol

Katherine Bongaerts, David C. Rubinsztein, Laura Oakley, Alimu Dayimu, Emma Cutting, Robyn Staples, Roger A. Barker, Katie Andresen, Nikolaos Demiris, Dimitrios Apostolopoulos, Wendy Gooding, Amy H Evans

August 1, 2024article en

3 citations

Abstract

No abstract available for this paper.

BMJ OpenVol. 14(8)

University of Cambridge (GB), Cambridge University Hospitals NHS Foundation Trust (GB), MRC Clinical Trials Unit at UCL (GB), UK Dementia Research Institute (GB), Institute for Medical Research (MY)

National Institute for Health and Care Research, Department of Health and Social Care, University of Cambridge, Cambridge University Hospitals, UK Dementia Research Institute, Medical Research Council, NIHR Cambridge Biomedical Research Centre

Openalex Percentile: Top 30%

Genetic Neurodegenerative Diseases

0.80

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Trial to assess the tolerability of using felodipine to upregulate autophagy as a treatment of Huntington’s disease (FELL-HD): a phase II, single-centre, open-label, dose-finding trial protocol — Katherine Bongaerts, David C. Rubinsztein, et al. · BMJ Open (2024) | TGRS Research Map | TGRS